The Gauteng Health Department has begun a phased rollout of Lenacapavir, a twice-yearly injection used for HIV prevention, across South Africa.
This initiative represents a significant shift in public health strategy by moving away from daily medication toward a long-acting injectable. By targeting high-risk populations in the province with the highest disease burden, officials aim to reduce the rate of new infections.
President Cyril Ramaphosa joined the launch of the program and said the rollout offers hope in the fight against HIV and AIDS [2]. The deployment focuses on the Gauteng province, where 133 health facilities [1] are participating in the initial phase of the program.
Health officials intend to treat 56,000 eligible people [1] who are identified as high-risk. The current phase of the rollout is scheduled to cover the next nine months [1]. This timeline allows the department to monitor the delivery system and patient adherence before expanding the program further.
Lenacapavir differs from previous prevention methods due to its administration schedule. While traditional prophylaxis often requires daily pills, this injection is administered only twice a year, removing the burden of daily adherence for the patient.
The Gauteng Health Department is coordinating the distribution across the selected facilities to ensure that those most vulnerable to infection have immediate access to the drug [1].
“The rollout offers hope in the fight against HIV and AIDS”
The transition to long-acting injectables like Lenacapavir addresses the primary failure of HIV prevention: adherence. By reducing the requirement from a daily pill to two shots per year, South Africa is attempting to close the gap between clinical availability and real-world usage, particularly among marginalized or high-risk groups who struggle with daily medication regimens.
